LFG Wealth Partners LLC Acquires Shares of 57,766 Pfizer Inc. $PFE

LFG Wealth Partners LLC purchased a new stake in shares of Pfizer Inc. (NYSE:PFE) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 57,766 shares of the biopharmaceutical company’s stock, valued at approximately $1,438,000.

A number of other hedge funds have also recently added to or reduced their stakes in PFE. Vanguard Group Inc. raised its stake in Pfizer by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock worth $13,479,520,000 after acquiring an additional 7,031,162 shares during the period. State Street Corp raised its position in shares of Pfizer by 0.5% during the 4th quarter. State Street Corp now owns 300,445,164 shares of the biopharmaceutical company’s stock worth $7,481,085,000 after purchasing an additional 1,357,756 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Pfizer by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 130,192,081 shares of the biopharmaceutical company’s stock worth $3,235,642,000 after purchasing an additional 1,184,728 shares during the last quarter. Morgan Stanley lifted its holdings in shares of Pfizer by 19.2% in the 4th quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock worth $2,218,929,000 after purchasing an additional 14,342,946 shares during the last quarter. Finally, Norges Bank acquired a new position in Pfizer during the 4th quarter valued at approximately $1,830,986,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. BMO Capital Markets reiterated an “outperform” rating and issued a $30.00 target price on shares of Pfizer in a research note on Monday, March 9th. Morgan Stanley increased their price objective on Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a research report on Friday, April 10th. Cantor Fitzgerald reiterated a “neutral” rating on shares of Pfizer in a research report on Monday, June 1st. Bank of America cut their target price on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Thursday, April 9th. Finally, Zacks Research upgraded Pfizer from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 24th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Pfizer has an average rating of “Hold” and a consensus price target of $28.82.

Pfizer Trading Down 0.8%

Shares of NYSE:PFE opened at $26.01 on Tuesday. The stock has a market capitalization of $148.24 billion, a PE ratio of 19.86 and a beta of 0.34. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. Pfizer Inc. has a one year low of $23.11 and a one year high of $28.75. The company’s 50-day moving average price is $26.38 and its two-hundred day moving average price is $26.33.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. The firm had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The company’s quarterly revenue was up 5.4% on a year-over-year basis. During the same period in the previous year, the company earned $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities analysts forecast that Pfizer Inc. will post 2.99 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, June 12th. Investors of record on Friday, May 8th were given a dividend of $0.43 per share. The ex-dividend date was Friday, May 8th. This represents a $1.72 annualized dividend and a yield of 6.6%. Pfizer’s dividend payout ratio (DPR) is currently 131.30%.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s CEO said the company could eventually return to high-single-digit growth, suggesting the business may be stronger than investors expect and improving the long-term growth narrative. Here’s When Pfizer’s CEO Says the Company Might Get Back to Generating High-Single-Digit Growth
• Positive Sentiment: Pfizer’s obesity pipeline got a boost after Phase 2b data for berobenatide showed proof of concept, favorable tolerability, and support for moving into Phase 3, which could add a new growth driver. Pfizer Obesity Pipeline Gains Traction As Berobenatide Data Support Valuation
• Positive Sentiment: RBC Capital upgraded Pfizer, reinforcing the view that the stock’s dividend and valuation may be attractive relative to peers. Pfizer (PFE) Upgraded at RBC Capital. Here is Why
• Neutral Sentiment: Pfizer is drawing heavy investor search interest and additional research coverage, indicating rising attention but not necessarily a direct fundamental catalyst. Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
• Neutral Sentiment: Analyst commentary continues to focus on Pfizer’s discounted valuation, fading COVID revenues, and looming patent expirations, leaving the stock’s longer-term rerating story still uncertain. Is Pfizer’s Discounted Valuation a Buying Opportunity or a Value Trap?
• Neutral Sentiment: Pfizer was also included in a “Top Research Reports” roundup, which adds visibility but does not appear to change the investment thesis on its own. Top Research Reports for Pfizer, Altria & Newmont Corp.
• Negative Sentiment: Ongoing concerns about patent cliffs and declining legacy COVID-related sales continue to cap enthusiasm for Pfizer’s near-term earnings growth. Is Pfizer’s Discounted Valuation a Buying Opportunity or a Value Trap?

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.